eff ect of HSP. Although all participants in our study were Chinese, we believe the results of the trial are generalizable to FC patients in the West only if the patients are also in excessive syndrome.
Th e group receiving placebo seemed to have less severe symptoms at baseline; however, there were no statistically significant diff erences for most of these outcome measures, including the number of complete spontaneous bowel movement. Th e changes of complete spontaneous bowel movement were used for determining the responder rates of HSP and placebo (primary outcome measures). Th erefore, it may not explain the low responder rate of HSP by comparing with other placebo-controlled FC trials on conventional medicine.
In previous studies on chronic constipation, the durations of treatment varied from 5 days to 7 months, while run-in period and post-treatment observation period were not included in most of studies ( 4 ) . We agree with Dr Whiting et al. that further studies for HSP in diff erent demographic characteristics and / or with longer treatment course and follow-up are worth to implement for assessing the efficacy of HSP.
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Th e authors declare no confl ict of interest. To the Editor: A 32-year-old lady was referred to our care in April 2006 with on and off epigastric discomfort. She had been inhaling ketamine for recreational use for 7 years, and also had lower urinary tract symptoms related to long-term ketamine use. Her liver function was deranged with an elevation of her serum alkaline phosphatase and gamma-glutamyl tansferase to 229 and 284 U / l, respectively; her bilirubin level and parenchymal liver enzymes were relatively normal. Endoscopic retrograde cholangiopancreatography (ERCP) showed multiple long-segment strictures and narrowing in the intrahepatic ducts of both lobes ( Figure 1 ) . Th e common bile duct was also mildly dilated with no fi lling defects. Th e pancreatic duct was normal. ERCP had been repeated nine times over the past 4 years with similar results; brush cytology of dominant strictures obtained each time revealed only reactive changes.
Ketamine-Induced
Additional investigations to exclude other causes of biliary disease had been performed. She was negative for anti-mitochondrial antibody (AMA), anti-nuclear antibody, and anti-HIV antibody. Her serum CA 19.9 and immunoglobulin G4 (IgG4) levels were normal. A liver biopsy with 12 portal tracts obtained in 2008 showed mild non-specifi c infl ammation of the portal tracts, with no portal or periductal fi brosis ( Figure 2 ). Th ere was no ductopenia to suggest primary biliary cirrhosis (PBC) and no significant portal fi brosis or heavy infl ammatory infi ltrates to suggest recurrent pyogenic cholangitis (RPC). Th e classical periductal " onion-skin " fi brosis suggestive of primary sclerosing cholangitis (PSC) was not seen. Colonoscopy with biopsies failed to show any evidence of coexisting infl ammatory bowel disease (IBD).
Ketamine is an N -methyl-D -aspartate antagonist that was fi rst used in clinical practice in the 1970s as an anesthetic. Its hallucinogenic side-eff ects and easy administration by inhalation has made it an increasingly common recreational drug. At low doses, it can result in euphoria and mild sensory and perceptual distortion. Higher doses can result in out-of-body and fl oating experiences. Its recreational use is extremely common in Asia, especially in Taiwan and Hong Kong. Its prevalence is also on the rise in the United Kingdom ( 1 ), especially in the adolescent population.
While long-term ketamine inhalation has been known to be associated with bladder dysfunction ( 2 ), its eff ects on the biliary system have been less well defi ned. An animal study has shown ketamine can increase the fl ow resistance across the sphincter of Oddi ( 3 ). Th ere has been only one report of three cases with biliary tract abnormalities associated with ketamine use ( 4 ), although important diff erential diagnoses have not been thoroughly excluded in these patients.
We postulate our patient ' s biliary abnormalities are the result of long-term ketamine usage. Important diff erential diagnoses for this patient include PBC, PSC, RPC, IgG4-positive sclerosing cholangitis, and AIDScholangiopathy. PBC is excluded based on a negative serum AMA and her abnormal cholangiograms. PSC is still a possible diagnosis, although it is a rare disease in Asia and its prevalence outside of Indian and Japan is unknown ( 5 ). Moreover, intrahepatic strictures in PSC are usually short and annular in a " beaded " pattern instead of the long strictures present in this patient. Th ere were also no histological features of PSC in her liver biopsy, and co existing IBD has been excluded. Although RPC is a common disease in South-East Asia, the lack of intrahepatic fi lling defects on multiple cholangiograms and the nonspecifi c biopsy fi ndings do not support this diagnosis. A normal serum IgG4 and a negative HIV status have excluded the remaining two diff erential diagnoses.
In conclusion, long-term ketamine usage can lead to gross biliary abnormalities resulting in recurrent epigastric discomfort and raised ductal enzymes. Clinicians should be aware of this association especially in countries where the recreational use of ketamine is rising.
